文献速递前列腺癌

经尿道超声消融(TULSA)治疗前列腺癌的系统综述与荟萃分析

Transurethral ultrasound ablation (TULSA) for prostate cancer: a systematic review and meta-analysis.
PubMed 文献 · BJU Int · 2026-10-12

该系统综述与荟萃分析纳入12项研究共630例患者,评估磁共振引导经尿道超声消融(TULSA)治疗原发性和复发性前列腺癌的肿瘤学、功能及安全性结局。原发TULSA的12个月csPCa无复发生存率为70%(95%CI 50-84),挽救性TULSA为80%(95%CI 66-89);无尿垫控尿率90%(95%CI 71-97),勃起功能保留率81%(95%CI 56-94),3级不良事件发生率6%(95%CI 4-11)。

要点

  • 原发TULSA的12个月csPCa无复发生存率为70%(95%CI 50-84)。
  • 挽救性TULSA的12个月csPCa无复发生存率为80%(95%CI 66-89)。
  • 无尿垫控尿率90%,勃起功能保留率81%,3级不良事件发生率6%。

核心结论

  • 原发TULSA是一种安全性较高的治疗方式,功能并发症风险低,但缺乏长期肿瘤学控制证据,技术和消融参数修改仍属实验性。
  • 挽救性TULSA数据较少,初步研究记录到相对较高的尿失禁率。

研究设计与样本

  • 系统检索MEDLINE、Embase、Web of Science和Scopus从建库至2025年7月,纳入12项研究共630例患者。
  • 630例中563例(89%)接受原发TULSA,57例(9%)接受挽救性TULSA,10例(2%)接受姑息性TULSA。

主要发现

  • 原发TULSA的12个月活检证实的临床显著前列腺癌(csPCa)无复发生存率为70%(95%CI 50-84)。
  • 挽救性TULSA的12个月csPCa无复发生存率为80%(95%CI 66-89)。
  • 按消融范围分层,全腺体TULSA的12个月csPCa无复发生存率为75%(95%CI 60-86),局灶TULSA为71%(95%CI 51-86)。
  • 无尿垫控尿率为90%(95%CI 71-97),勃起功能保留率为81%(95%CI 56-94)。
  • 3级严重不良事件发生率为6%(95%CI 4-11)。

临床怎么用

  • 原发TULSA可作为功能保护要求较高的前列腺癌患者的治疗选择,但需告知长期肿瘤学控制证据不足。
  • 挽救性TULSA需谨慎选择患者,因初步数据显示尿失禁率相对较高。

局限性

  • 多个结局存在异质性,可能反映纳入研究在终点定义、治疗方式和随访方案上的差异。
  • 缺乏长期肿瘤学控制证据,治疗技术和消融参数的修改仍属实验性。
  • 挽救性TULSA数据较少。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Our objective was to synthesise evidence on oncological, functional and safety outcomes of magnetic resonance imaging-guided transurethral ultrasound ablation (TULSA) for primary and recurrent prostate cancer. METHODS: MEDLINE, Embase, Web of Science and Scopus were systematically searched from inception to July 2025. The primary outcomes were 12-month biopsy-proven clinically significant prostate cancer (csPCa) recurrence-free survival (RFS) and rates of pad-free continence and preserved erectile function at last follow-up. Secondary outcomes included biochemical recurrence, progression to salvage treatment and rates of adverse effects. RESULTS: Twelve studies comprising 630 patients were analysed. In total, 563 (89%) patients underwent primary TULSA, 57 (9%) patients underwent salvage TULSA, and 10 (2%) patients had palliative TULSA. Pooled 12-month csPCa RFS was 70% (95% confidence interval [CI] 50-84) for primary TULSA and 80% (95% CI 66-89) for salvage TULSA. Stratifying by ablation fraction, pooled 12-month csPCa RFS was 75% (95% CI 60-86) for whole-gland TULSA, and 71% (95% CI 51-86) for focal TULSA. The proportion of pad-free continence was 90% (95% CI 71-97), and the rate of preservation of erectile function was 81% (95% CI 56-94). Incidence of grade 3 severity adverse events was 6% (95% CI 4-11). There was heterogeneity in multiple outcomes, likely reflecting variation in endpoint definitions, treatment approaches and follow-up protocols among the included studies. CONCLUSION: Primary TULSA is a safe treatment modality with a low risk of functional morbidity. However, there is a lack of evidence on long-term oncological control, with modifications of the treatment technique and ablation parameters still being experimental. Fewer data are available for salvage TULSA, where preliminary studies have recorded relatively high rates of incontinence.

来源:BJU Int,查看原文。版权归原作者所有。

引用

  1. Wang E, Wei X, Dua Y, et al. Transurethral ultrasound ablation (TULSA) for prostate cancer: a systematic review and meta-analysis. BJU Int. 2026. PMID: 42864969. doi:10.1111/bju.70471

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。